Mayne Pharma Group Limited (MYX) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Mayne Pharma Group Ltd..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.537 -- 00:00:05.043 Good morning, everyone, and thank you for joining Maine Pharma's One Age Fiscal 26 results 00:00:05.043 -- 00:00:09.728 presentation. Today, we will cover the group financial outcome for the half, then take 00:00:09.728 -- 00:00:14.675 you through each segment, women's health, dermatology, and international, before finishing 00:00:14.675 -- 00:00:19.861 with our Fiscal 26 focus and outlook. As investors will appreciate, we have already provided 00:00:19.861 -- 00:00:25.208 a set of our unaudited numbers within our presentation at the company's 2025 00:00:25.208 -- 00:00:29.528 Annual General Meeting on 29 January, 2026. 00:00:29.528 -- 00:00:34.256 Before we begin the formal aspects of today's presentation, as we announced to the market 00:00:34.256 -- 00:00:39.564 this morning, Main Pharma is undertaking a planned and orderly leadership transition, 00:00:39.564 -- 00:00:45.214 with Sean Patrick O'Brien stepping down as Chief Executive Officer and Managing Director, 00:00:45.214 -- 00:00:49.858 and with me having been appointed Chief Executive Officer, 00:00:51.464 -- 00:00:56.807 both effective from February 21. This transition is part of the board structured succession 00:00:56.807 -- 00:01:01.815 process and is designed to maintain momentum and execution with continuity 00:01:01.815 -- 00:01:05.460 of strategy, governance, and financial discipline. 00:01:05.460 -- 00:01:09.807 Importantly, the business remains stable with a strong, experienced leadership team in 00:01:09.807 -- 00:01:13.352 place across our key functions and business units. 00:01:13.352 -- 00:01:18.720 And we are continuing to operate exactly as planned with a focus on performance, outcomes, 00:01:18.720 -- 00:01:24.528 and disciplined allocation of capital. I w...